The efficacy of biologic therapies is proven and their use is growing worldwide; however, there is concern about their long-term safety, including the risk of developing cancer. In this Review, data available on the association of anti-tumor necrosis factor therapies and the anti-α4 integrin monoclonal antibody natalizumab with cancer in patients with IBD are discussed.
- Livia Biancone
- Emma Calabrese
- Francesco Pallone